1. No category

Hikma Meet the Management Day London
London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY),
the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London
on Tuesday 2 December 2014.
The event will take place at The Westbury Hotel, 2nd Floor Westbury Gallery, Bond Street, London,
W1S 2YF from 9.30am through to 2.30pm.
Our confirmed Management for the event are listed below. Hikma Management will be spread out
across 4 meeting rooms and investors & analysts will rotate rooms to meet everyone in 4 Q&A slots.
Corporate Focus:
Said Darwazah, Chairman & CEO
Bassam Kanaan, President and Chief Operating Officer for MENA and EU Region
Khalid Nabilsi, CFO
MENA Focus:
Mazen Darwazah, President & CEO MENA and Emerging Markets
Salah Mawajdah, Corporate Vice President Regulatory & Medical Affairs
Hassan Shafiq, Managing Director, Hikma Egypt
Basel Ziyadeh, General Manager / GCC
US Generics Focus:
Mike Raya, CEO West-Ward Pharmaceuticals
Brian Hoffman, VP Corporate Development West-Ward Pharmaceuticals
Fadi Nassar, Corporate VP API
Injectables Focus:
Riad Mishlawi, Vice President & Global Head of Injectables
Spiro Gavaris, VP Sales and Marketing West-Ward Pharmaceuticals
Natheer Masarweh, VP Quality Global Injectables and Operations (Portugal)
If you are interested in attending this event please contact Kate Komornicka [email protected] to
register your interest and for further details.
-- ENDS --
1
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations
Lucinda Henderson, Deputy Head of Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
+44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing
and marketing a broad range of both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in
the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.
In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212
million.
2